FDA OKs Roche’s Zelboraf for rare blood disease
US regulators have approved Roche’s Zelboraf (vemurafenib) for patients with a rare blood condition called Erdheim-Chester disease (ECD) carrying a mutation called BRAF V600
Read More
Tag: vemurafenib
Roche pushes Tecentriq combos into PhIII melanoma trials
Roche is planning to initiate late-stage studies investigating potential combinations for patients with advanced skin cancer based on its immunotherapy Tecentriq, which is already on the market for lung and bladder cancer.
Read More
NICE rejects Roche’s melanoma combo
Patients in England and Wales with a certain type of advanced skin cancer will not be getting routine access to Roche’s Cotellic/Zelboraf combination on the NHS, after it was turned down by the National Institute for Health and Care Excellence.
Read More
- PMGroup Worldwide Ltd welcomes MAD World Summit
- Argenx receives review from FDA for VYVGART in seronegative gMG
- Nuclera extends Series C funding to advance antibody engineering
- Cellistic launches new iPSC-based platforms to expand immuno-oncology therapies
- Fabentech secures French approval for Ricimed antidote
